Propofol Suppresses Cell Progression by Inhibiting CCL18 Expression in Hepatoblastoma
暂无分享,去创建一个
[1] Y. Nagahara,et al. BRAP2 inhibits the Ras/Raf/MEK and PI3K/Akt pathways in leukemia cells, thereby inducing apoptosis and inhibiting cell growth. , 2021, Experimental and therapeutic medicine.
[2] S. Elloumi,et al. Effect of Compound Propofol Nanoemulsion on Immune Function in Patients with Pancreatic Cancer. , 2021, Journal of Nanoscience and Nanotechnology.
[3] M. Struys,et al. Prospective clinical validation of the Eleveld propofol pharmacokinetic-pharmacodynamic model in general anaesthesia. , 2020, British journal of anaesthesia.
[4] P. Dzięgiel,et al. CCL18 in the Progression of Cancer , 2020, International journal of molecular sciences.
[5] T. Kanematsu,et al. The indirect γ-aminobutyric acid (GABA) receptor agonist gabaculine-induced loss of the righting reflex may inhibit the descending analgesic pathway , 2020, Pharmacology Biochemistry and Behavior.
[6] Yurong Song,et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers , 2020, Cell Death & Disease.
[7] Xiao Jiang,et al. CCL18-NIR1 promotes oral cancer cell growth and metastasis by activating the JAK2/STAT3 signaling pathway , 2020, BMC Cancer.
[8] Yichi Xu,et al. Effects of propofol on the development of cancer in humans , 2020, Cell proliferation.
[9] Juan Peng,et al. Role of PI3K/AKT pathway in cancer: the framework of malignant behavior , 2020, Molecular Biology Reports.
[10] Yi-long Wu,et al. Germline variation networks in the PI3K/AKT pathway corresponding to familial high-incidence lung cancer pedigrees , 2020, BMC Cancer.
[11] R. Alaggio,et al. Hepatoblastoma and Pediatric Hepatocellular Carcinoma: An Update , 2020, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.
[12] Yan Sun,et al. Propofol exerts anticancer activity on hepatocellular carcinoma cells by raising lncRNA DGCR5 , 2020, Journal of cellular physiology.
[13] N. Zhang,et al. Effects of different doses of propofol on the growth and expression of PCNA, CD34 and pAKT proteins in xenografted tumor of BALB/C mice with liver cancer , 2020, Clinical and Translational Oncology.
[14] Yunfeng Huang,et al. Propofol Improves Sensitivity of Lung Cancer Cells to Cisplatin and Its Mechanism , 2020, Medical science monitor : international medical journal of experimental and clinical research.
[15] Xihua Lu,et al. Effects of propofol on colon cancer metastasis through STAT3/HOTAIR axis by activating WIF‐1 and suppressing Wnt pathway , 2020, Cancer medicine.
[16] Ling Ye,et al. Propofol inhibits proliferation and cisplatin resistance in ovarian cancer cells through regulating the microRNA-374a/forkhead box O1 signaling axis , 2020, Molecular medicine reports.
[17] Fang-xiang Zhang,et al. Propofol affects the growth and metastasis of pancreatic cancer via ADAM8 , 2019, Pharmacological Reports.
[18] S. Hahn,et al. Evaluation of the safety of using propofol for paediatric procedural sedation: A systematic review and meta-analysis , 2019, Scientific Reports.
[19] Yan-tao Fu,et al. Propofol inhibits proliferation, migration, and invasion of hepatocellular carcinoma cells by downregulating Twist , 2019, Journal of cellular biochemistry.
[20] G. Zhu,et al. CCL18 promotes the metastasis of squamous cell carcinoma of the head and neck through MTDH‐NF‐κB signalling pathway , 2019, Journal of cellular and molecular medicine.
[21] Xiaobin Lv,et al. Macrophage-derived CCL18 promotes osteosarcoma proliferation and migration by upregulating the expression of UCA1 , 2018, Journal of Molecular Medicine.
[22] Zhenfei Hu,et al. Propofol Inhibits Proliferation, Migration, Invasion and Promotes Apoptosis Through Down-Regulating miR-374a in Hepatocarcinoma Cell Lines , 2018, Cellular Physiology and Biochemistry.
[23] Michel M. R. F. Struys,et al. Clinical Pharmacokinetics and Pharmacodynamics of Propofol , 2018, Clinical Pharmacokinetics.
[24] M. Buendia,et al. New insights into diagnosis and therapeutic options for proliferative hepatoblastoma , 2018, Hepatology.
[25] Weidong Wei,et al. Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials , 2018, PloS one.
[26] C. Rancourt,et al. CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling , 2016, Molecular Cancer.
[27] Yunjie Zeng,et al. CCL18/PITPNM3 enhances migration, invasion, and EMT through the NF-κB signaling pathway in hepatocellular carcinoma , 2016, Tumor Biology.
[28] M. Ling,et al. The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses , 2015, Molecular Cancer.
[29] 신동훈,et al. 성인에서 발생한 Hepatoblastoma , 1999 .